ATE468137T1 - Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten - Google Patents

Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten

Info

Publication number
ATE468137T1
ATE468137T1 AT02717057T AT02717057T ATE468137T1 AT E468137 T1 ATE468137 T1 AT E468137T1 AT 02717057 T AT02717057 T AT 02717057T AT 02717057 T AT02717057 T AT 02717057T AT E468137 T1 ATE468137 T1 AT E468137T1
Authority
AT
Austria
Prior art keywords
treatment
hmgb1
inhibitors
tissue diseases
hmg box
Prior art date
Application number
AT02717057T
Other languages
English (en)
Inventor
Marco Bianchi
Tiziana Bonaldi
Paola Scaffidi
Susanne Mueller
Bernard Degryse
Original Assignee
Bio3 Res S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio3 Res S R L filed Critical Bio3 Res S R L
Application granted granted Critical
Publication of ATE468137T1 publication Critical patent/ATE468137T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
AT02717057T 2001-03-16 2002-03-12 Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten ATE468137T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001MI000562A ITMI20010562A1 (it) 2001-03-16 2001-03-16 Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari
PCT/IT2002/000153 WO2002074337A1 (en) 2001-03-16 2002-03-12 Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases

Publications (1)

Publication Number Publication Date
ATE468137T1 true ATE468137T1 (de) 2010-06-15

Family

ID=11447291

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02717057T ATE468137T1 (de) 2001-03-16 2002-03-12 Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten

Country Status (15)

Country Link
US (4) US7754217B2 (de)
EP (1) EP1368060B1 (de)
JP (1) JP4822654B2 (de)
CN (2) CN101773669A (de)
AT (1) ATE468137T1 (de)
AU (1) AU2002247977C1 (de)
CA (1) CA2439530C (de)
DE (1) DE60236413D1 (de)
DK (1) DK1368060T3 (de)
ES (1) ES2346408T3 (de)
HK (1) HK1069316A1 (de)
IT (1) ITMI20010562A1 (de)
MX (1) MXPA03008364A (de)
PT (1) PT1368060E (de)
WO (1) WO2002074337A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7151082B2 (en) 1999-02-11 2006-12-19 The Feinstein Institute For Medical Research Antagonists of HMG1 for treating inflammatory conditions
US7754217B2 (en) * 2001-03-16 2010-07-13 Bio3 Research Srl HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases
CZ20033402A3 (cs) * 2001-05-15 2004-10-13 Northáshore@Longáislandájewisháresearcháinstitute Použití fragmentů HMG jako protizánětlivých činidel
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US7220723B2 (en) 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
JP2005537253A (ja) 2002-07-03 2005-12-08 フォンダッチォーネ・セントロ・サン・ラファエル・デル・モンテ・タボール 組織損傷の治療におけるおよび／または組織修復を促進するためのｈｍｇｂ１の使用
JP2006517537A (ja) * 2003-01-03 2006-07-27 アルケド バイオテック ゲーエムベーハー Ｄｎａ結合タンパク質の使用
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
JP4792392B2 (ja) 2003-09-11 2011-10-12 コーナーストーン セラピューティクス インコーポレイテッド Ｈｍｇｂ１に対するモノクローナル抗体
ITRM20040058A1 (it) * 2004-02-03 2004-05-03 Marco E Bianchi Inibitori ed antagonisti di hmgb1 in grado di regolare la proliferazione delle cellule muscolari lisce ed endoteliali.
EP1768677B1 (de) * 2004-07-02 2008-06-25 Creabilis Therapeutics S.P.A. Nukleinsäuren zur behandlung von erkrankungen im zusammenhang mit hmgb1
EP1768693A1 (de) 2004-07-20 2007-04-04 Provincia Italiana Della Congregazione Dei Figli Dell'Immacolata Concezione - Istituto Dermopatico Dell'Immacolata Verwendung von hmgb1 zur wundheilung
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
EP1797118A2 (de) * 2004-09-03 2007-06-20 Creabilis Therapeutics S.P.A. Protease resistente mutanten von humanem und nicht-humanem hmgb1 box-a protein und dessen therapeutische/diagnistische verwendung
CN101132811B (zh) 2004-10-22 2012-05-30 米迪缪尼有限公司 抗hmgb1的高亲和力抗体及其用法
US8129130B2 (en) 2004-10-22 2012-03-06 The Feinstein Institute For Medical Research High affinity antibodies against HMGB1 and methods of use thereof
ITRM20050032A1 (it) * 2005-01-21 2006-07-22 Marco E Bianchi Inibitori ed antagonisti di hmgb1 in grado di inibire la patogenesi e la progressione della malattia aterosclerotica.
WO2006114805A2 (en) * 2005-04-28 2006-11-02 Fondazione Centro San Raffaele Del Monte Tabor Use of hmgb2 and hmgb3 proteins for medical applications
EP1909834A2 (de) 2005-07-18 2008-04-16 Critical Therapeutics, Inc. Verwendung von hmgb1-antagonisten zur behandlung von entzündungskrankheiten
PT1919979E (pt) 2005-08-25 2014-03-07 Creabilis Therapeutics Spa Polímeros conjugados de k-252a e seus derivados
WO2007031100A1 (en) * 2005-09-14 2007-03-22 Ostini, Marco Active immunotherapy of life-threatening systemic inflammation
EP1959997A4 (de) 2005-11-28 2009-12-23 Medimmune Llc Antagonisten von hmgb1 und/oder rage und verwendungsverfahren dafür
US7829097B2 (en) * 2006-02-06 2010-11-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of HMGB1 for protection against ischemia reperfusion injury
JP2010503630A (ja) 2006-09-15 2010-02-04 クレアビリス・セラピューティクス・エスピーエー ＨＭＧＢ１のＢｏｘ−ＡおよびＨＭＧＢ１のＢｏｘ−Ａ変異体のポリマー複合体
TW200902063A (en) 2007-02-15 2009-01-16 Univ Kumamoto Therapeutic agent comprising antibody capable of specifically binding to human hmgb-1 as active ingredient
US9919010B2 (en) 2008-04-30 2018-03-20 Genomix Co., Ltd. Method for collecting functional cells in vivo with high efficiency
RU2519714C2 (ru) 2008-04-30 2014-06-20 Дженомикс Ко., Лтд. Средство для вовлечения происходящей из костного мозга плюрипотентной стволовой клетки в периферический кровоток
US9278108B2 (en) 2009-07-16 2016-03-08 Nec Solution Innovators, Ltd. HMGB1 binding nucleic acid molecule and applications thereof
JP5467313B2 (ja) 2009-09-28 2014-04-09 国立大学法人 岡山大学 アテローム動脈硬化抑制剤
RU2599448C2 (ru) 2009-10-28 2016-10-10 Дженомикс Ко., Лтд. Средства для стимуляции регенерации тканей путем привлечения мезенхимных стволовых клеток и/или плюрипотентных стволовых клеток костного мозга в кровь
ES2715204T3 (es) 2010-10-30 2019-06-03 Univ Oxford Innovation Ltd Tratamiento de la enfermedad de Dupuytren
US10364276B2 (en) 2011-04-26 2019-07-30 StemRIM Inc. Peptide for inducing regeneration of tissue and use thereof
US9561274B2 (en) 2011-06-07 2017-02-07 University Of Hawaii Treatment and prevention of cancer with HMGB1 antagonists
WO2012170740A2 (en) * 2011-06-07 2012-12-13 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
JP6253589B2 (ja) 2012-10-25 2017-12-27 株式会社ジェノミックス Ｈｍｇｂ１断片を利用した新規心筋梗塞の治療法
KR102146822B1 (ko) 2012-10-25 2020-08-21 가부시키가이샤 스템림 Hmgb1 단편을 이용한 척수 손상에 대한 신규 치료법
CA2897914A1 (en) 2013-01-28 2014-07-31 Evec Inc. Humanized anti-hmgb1 antibody or antigen-binding fragment thereof
IL242807A0 (en) 2015-11-26 2016-04-21 Novamed Ltd Test facility
AU2016366515A1 (en) 2015-12-11 2018-06-21 Ruprecht-Karls-Universität Heidelberg Combined preparations of PKM2 modulators and HMGB1
BR112019014921A2 (pt) 2017-01-27 2020-03-31 StemRIM Inc. Agente terapêutico para miocardiopatia, infarto antigo do miocárdio e insuficiência cardíaca crônica
EP3718561A4 (de) 2017-12-01 2021-07-21 Stemrim Inc. Therapeutikum für entzündliche darmerkrankung
WO2021242180A1 (en) * 2020-04-22 2021-12-02 Chulalongkorn University A composition and a method of rejuvenating dna and preventing dna damage

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054122A (en) * 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US5470307A (en) * 1994-03-16 1995-11-28 Lindall; Arnold W. Catheter system for controllably releasing a therapeutic agent at a remote tissue site
WO1997026913A1 (en) 1996-01-26 1997-07-31 The Trustees Of Columbia University In The City Of New York A POLYPEPTIDE FROM LUNG EXTRACT WHICH BINDS AMYLOID-β PEPTIDE
US5864018A (en) * 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
WO1997039121A1 (en) 1996-04-16 1997-10-23 Schering Aktiengesellschaft Advanced glycosylation end-product receptor peptides and uses therefor
US6790443B2 (en) 1996-11-22 2004-09-14 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US6398808B1 (en) * 1999-06-15 2002-06-04 Scimed Life Systems, Inc. Localized delivery of genetic information from biostable materials
US7754217B2 (en) * 2001-03-16 2010-07-13 Bio3 Research Srl HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases
CZ20033402A3 (cs) * 2001-05-15 2004-10-13 Northáshore@Longáislandájewisháresearcháinstitute Použití fragmentů HMG jako protizánětlivých činidel
ITRM20040058A1 (it) * 2004-02-03 2004-05-03 Marco E Bianchi Inibitori ed antagonisti di hmgb1 in grado di regolare la proliferazione delle cellule muscolari lisce ed endoteliali.
EP1768693A1 (de) * 2004-07-20 2007-04-04 Provincia Italiana Della Congregazione Dei Figli Dell'Immacolata Concezione - Istituto Dermopatico Dell'Immacolata Verwendung von hmgb1 zur wundheilung
WO2008137552A2 (en) * 2007-05-02 2008-11-13 Medimmune, Llc Anti-rage antibodies and methods of use thereof

Also Published As

Publication number Publication date
US20100172896A1 (en) 2010-07-08
CN1537014B (zh) 2012-04-25
JP2004523579A (ja) 2004-08-05
DE60236413D1 (de) 2010-07-01
MXPA03008364A (es) 2004-11-12
US8058239B2 (en) 2011-11-15
US20100297107A1 (en) 2010-11-25
AU2002247977B8 (en) 2007-03-15
CA2439530C (en) 2016-11-08
EP1368060A1 (de) 2003-12-10
HK1069316A1 (en) 2005-05-20
WO2002074337A8 (en) 2003-08-28
WO2002074337A1 (en) 2002-09-26
JP4822654B2 (ja) 2011-11-24
DK1368060T3 (da) 2010-08-30
AU2002247977A2 (en) 2004-02-26
EP1368060B1 (de) 2010-05-19
PT1368060E (pt) 2010-08-24
AU2002247977B2 (en) 2006-12-14
US20080171052A1 (en) 2008-07-17
ITMI20010562A1 (it) 2002-09-16
AU2002247977C1 (en) 2008-09-18
AU2002247977A1 (en) 2002-10-03
CN1537014A (zh) 2004-10-13
ES2346408T3 (es) 2010-10-15
US20040136979A1 (en) 2004-07-15
US7754217B2 (en) 2010-07-13
CA2439530A1 (en) 2002-09-26
CN101773669A (zh) 2010-07-14

Similar Documents

Publication Publication Date Title
ATE468137T1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
MXPA03006771A (es) Anticuerpos modificados y metodos de uso.
ATE331534T1 (de) Anwendung von zielgerichtetem radium 223 für palliative und therapeutische behandlung von knochenkrebs
DE69625691T2 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
DE60327622D1 (de) Kombinierte antitachykardie - schrittmacher und hochspannungstherapie zur behandlung von ventrikulären arrhythmien
CY1105818T1 (el) Χρησεις του et743 στην θepαπευτικη αγωγη του καρκινου
DE60028863D1 (de) Elektrochirurgisches Handstück zur Behandlung von Gewebe
DE69918687D1 (de) 4-phenylpiperidine zur behandlung von prutitischen hauterkrankungen
ATE254461T1 (de) Behandlung von augenschmerzen
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DE50010284D1 (de) Arzneimittel zur behandlung von bluthochdruck
DE60027209D1 (de) Arzneimittel enthaltend hydroxyapatite zur behandlung von knochengewebserkrankungen
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
SE9904674D0 (sv) Novel compounds
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DE60223707D1 (de) Calcium-l-threonat zur behandlung von knochenfrakturen
EA200200853A1 (ru) Применение 2-метилтиазолидин-3,3-дикарбоновой кислоты (2-мтдк) и/или ее физиологически совместимых солей для лечения и/или предупреждения рака
ATE330596T1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
ATE264101T1 (de) Verwendung von thioamidoxazolidinonen zur behandlung von knochenresorption und osteoporose
ATE545421T1 (de) Pharmazeutisches präparat zur behandlung von parasitären tropenkrankheiten enthaltend diminazen-di-aceturat

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1368060

Country of ref document: EP